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Lipid homeostasis is transcriptionally regulated by
three DNA-binding proteins, designated sterol regula-
tory element-binding protein (SREBP)-1a, -1c, and -2.
Oligonucleotide arrays hybridized with RNA made from
livers of transgenic SREBP-1a, transgenic SREBP-2, and
SREBP cleavage-activating protein knockout mice re-
cently identified 33 genes regulated by SREBPs in liver,
four of which had no known connection to lipid metab-
olism. One of the four genes was PCSK9, which encodes
proprotein convertase subtilisin/kexin type 9a, a protein
that belongs to the proteinase K subfamily of subtilases.
Mutations in PCSK9 are associated with an autosomal
dominant form of hypercholesterolemia. Here, we dem-
onstrate that hepatic overexpression of either wild-type
or mutant PCSK9 in mice results in hypercholesterol-
emia. The hypercholesterolemia is due to a post-tran-
scriptional event causing a reduction in low density
lipoprotein (LDL) receptor protein prior to the internal-
ization and recycling of the receptor. Overexpression of
PCSK9 in primary hepatocytes and in mice lacking the
LDL receptor does not alter apolipoprotein B secretion.
These data are consistent with PCSK9 affecting plasma
LDL cholesterol levels by altering LDL receptor protein
levels via a post-transcriptional mechanism.
Plasma LDL1 cholesterol concentrations are determined by
the relative rates of VLDL and LDL production by the liver and
the rate of LDL uptake via hepatic LDL receptors (LDLRs) (1,
2). VLDL secretion from hepatocytes is positively correlated
with rates of hepatic lipid synthesis (3). Genes required for
cholesterol and triglyceride biosynthesis and, thus, VLDL pro-
duction are regulated by three sterol regulatory element-bind-
ing proteins (SREBPs), SREBP-1a, SREBP-1c, and SREBP-2
(4, 5). SREBPs also are the principal transcriptional regulators
of the LDL receptor gene, which clears apoB-containing li-
poproteins, such as VLDL and LDL, from the plasma (5).
To identify genes regulated by SREBPs, we used oligonucleo-
tide arrays hybridized with RNA from livers of mice that over-
expressed SREBPs (transgenic for SREBP-1a or transgenic for
SREBP-2) and that lacked all SREBPs as a result of deleting
SCAP, an escort protein required for SREBP activation (5).
With this physiologic filter, 33 genes were identified that were
increased in the transgenic livers and decreased in the SCAP-
deficient livers. Four of these 33 genes had no known function.
One of these four genes was Pcsk9, which encodes the propro-
tein convertase subtilisin/kexin type 9a, also designated
NARC-1 (neural apoptosis-regulated convertase 1). Seidah et
al. (6) showed that PCSK9 belongs to the proteinase K subfam-
ily of subtilases. PCSK9 is synthesized first as a soluble zymo-
gen that undergoes autocatalytic intramolecular processing in
the ER to produce a prosegment that remains associated with
the secreted enzyme.
A link between PCSK9 and cholesterol metabolism was es-
tablished by Abifadel et al. (7), who showed that two missense
mutations in PCSK9 were associated with an autosomal dom-
inant form of hypercholesterolemia. The first mutation results
in the substitution of an arginine for serine (S127R) in a con-
served residue located between the primary and secondary
zymogen processing sites. The second missense mutation
(F216L), also in a conserved amino acid, is in the catalytic
domain of the enzyme. Subsequently, two additional missense
mutations in the catalytic domain of PCSK9 (D374Y and
N157K) were shown to segregate in families with elevated
plasma LDL cholesterol concentrations (8, 9).
The clinical phenotype of subjects with these missense mu-
tations in PCSK9 is indistinguishable from two other autoso-
mal dominant forms of hypercholesterolemia, familial hyper-
cholesterolemia, which is caused by mutations in the LDLR
and familial defective apoB, due to mutations that interfere
with LDL binding to the LDLR and clearance from the plasma
(10). We hypothesized that mutations in PCSK9 cause hyper-
cholesterolemia by altering SREBP expression, apoB synthesis/
secretion, and/or LDLR expression. To distinguish between
these mechanisms, a series of in vitro and in vivo studies with
wild-type and mutant PCSK9 was performed.
EXPERIMENTAL PROCEDURES
General Methods and Supplies—DNA manipulations were per-
formed using standard molecular biology techniques (11). The concen-
trations of cholesterol and triglycerides in plasma were measured as
described previously (12). Plasma lipoprotein fractions were separated
by fast performance liquid chromatography (FPLC) gel filtration using
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a Superose 6 column, and cholesterol concentrations were measured as
described (13, 14). Protein concentrations were determined using a BCA
kit (Pierce). Newborn calf lipoprotein-deficient serum (NCLPDS) (d 
1.215 mg/ml) was prepared as described (15). Other reagents otherwise
not specified were obtained from Sigma.
Expression plasmids pTK-HSV-BP1 and pTK-HSV-BP2, encoding
wild-type HSV-tagged full-length human SREBP-1 or SREBP-2 (16),
and pCMV-S1P-Myc, encoding hamster S1P (17), were constructed as
described in the indicated references.
Antibodies and Immunoblot Analyses—The following monoclonal an-
tibodies were used in the current studies: anti-HSV (IgG1) from EMD
Biosciences (Novagen Brand, Madison, WI), anti-Myc (clone 9E10) from
Roche Applied Science, anti-FLAG (M2) from Sigma, anti-human trans-
ferrin receptor from Zymed Laboratories (South San Francisco, CA),
polyclonal anti-human cAMP-responsive element-binding protein from
Cell Signaling Technology, Inc. (Beverly, MA), horseradish peroxidase-
conjugated donkey anti-mouse IgG from Jackson ImmunoResearch
Laboratories (West Grove, PA), and horseradish peroxidase-conjugated
donkey anti-rabbit IgG (affinity-purified) from Amersham Biosciences.
Polyclonal antibodies against the mouse LDLR, LDL receptor-related
protein (LRP), receptor-associated protein (RAP), ARH, SREBP-1, and
SREBP-2 were described previously (12, 18–23). Immunoblot analyses
were performed using the SuperSignal West Pico Chemiluminescent
Substrate System from Pierce.
Construction of Wild-type and Mutant PCSK9 Expression Vec-
tors—An expression vector that encodes amino acids 1–692 of human
PCSK9 followed by a FLAG epitope tag (DYKDDDDK) under the con-
trol of the CMV promoter-enhancer (pCMV-PCSK9-FLAG) was con-
structed as follows. The human PCSK9 cDNA was amplified using
nested PCR. First-strand cDNA was synthesized from total RNA pre-
pared from cultured HepG2 cells (ATCC number HB-8065) using meth-
ods described previously (24). The following primers were then used for
the amplification of the PCSK9 cDNA: 5 primer (5-GCAACCTCTCC-
CCTGGCCCTCATG-3) and 3 primer (5-GCTTCCTGGCACCTCCAC-
CTGGGG-3) for the primary amplification and 5 primer (5-CCAGT-
GTGCTGGAATTCGCCACCATGGGCACCGTCAGCTCCAGG-3) and
3 primer (5-CCCCTCGAGTCACTCACTTGTCATCGTCGTCCTTGTA-
GTCCTGGAG CTCCTGGGAGGCCTGCGCCAG-3) for the secondary
amplification. The 5 primer sequence for the secondary amplification
contained an EcoRI restriction site, a Kozak sequence, and the sequence
encoding amino acids 1–7 of human PCSK9. The sequence of 3 primer
used for the secondary amplification consisted of nucleotides that en-
code amino acids 684–692 of human PCSK9, a FLAG epitope tag, two
copies of a stop codon with an intervening G nucleotide, and an XhoI
restriction site. The PCR-amplified cDNA for human PCSK9 was di-
gested with EcoRI and XhoI prior to ligation into pcDNA3 (Invitrogen).
To generate plasmids expressing mutant forms of human PCSK9, the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA)
was used to change the nucleotide sequences of pCMV-PCSK9-FLAG
using the following oligonucleotides: 5-CTTCCTGGTGAAGATGAGA-
GGCGACCTGCTGGAGCTG-3 for the S127R plasmid (pCMV-S127R),
5-GAGGAGGACGGGACCCGCCTCCACAGACAGGCCAGCA-3 for
the F216L plasmid (pCMV-F216L), and 5-ACAGAGTGGGACAGCCCA-
GGCTGCTGCCC-3 for the S386A plasmid (pCMV-S386A). The integrity
of expression plasmid sequences was confirmed by DNA sequencing.
Cultured Cell Experiments—Cells were cultured in one of the follow-
ing media. Medium A contained a 1:1 mixture (v/v) of Ham’s F-12
medium and Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen)
containing 100 units/ml penicillin and 100 g/ml streptomycin sulfate.
Medium B contained medium A supplemented with 5% (v/v) fetal calf
serum (FCS), 5 g/ml cholesterol, 1 mM sodium mevalonate, and 20 M
sodium oleate. Medium C contained medium A supplemented with 5%
(v/v) NCLPDS, 50 M sodium compactin, and 50 M sodiummevalonate.
SRD-12B cells that harbor a genetic deletion of S1P (25) were set up
at 5  105 cells/60-mm dish in medium B on day 0. On day 1, cells were
transfected with the indicated plasmids (2 g of DNA/dish) using 6 l of
Fugene 6 (Roche Applied Science) as described (26). On day 2, cells were
washed twice with phosphate-buffered saline and cultured for 1 h in
medium C containing 1% (w/v) hydroxypropyl--cyclodextrin. After in-
cubation at 37 °C for 1 h, cells were washed twice with phosphate-
buffered saline and cultured in medium C in the absence or presence of
1 g/ml 25-hydroxycholesterol plus 10 g/ml cholesterol added in a final
concentration of 0.2% ethanol. After a 4-h incubation,N-acetyl-leucinal-
leucinal-norleucinal (25 g/ml) was added for 1 h, after which the cells
were harvested and processed as described (27).
HepG2 cells (ATCC number HB-8065) were set up at 5  105 cells/
60-mm dish in DMEM containing 100 units/ml penicillin and 100 g/ml
streptomycin sulfate (medium D) supplemented with 10% FCS on day
0. On day 1, cells were infected with the indicated adenovirus described
below in 1 ml of medium D. After a 2-h incubation, 1 ml of medium D
supplemented with 20% NCLPDS was added and incubated overnight
at 37 °C. After an overnight incubation, the cells were harvested and
processed as described above.
Stable Transfection of Chinese Hamster Ovarian (CHO-K1) Cells—
On day 0, CHO-K1 cells (ATCC number CCL-61) were plated at a
density of 5  104 cells/100-mm dish in medium A supplemented with
5% (v/v) FCS. On day 1, cells were transfected with 5 g of pCMV-
PCSK9-FLAG, pCMV-S127R, or pCMV-F216L per dish using the Fu-
gene 6 reagent in a final volume of 0.2 ml. To generate control stable cell
lines, 1 g of pcDNA3 was used to transfect CHO-K1 cells. On day 2, the
medium was changed to medium A containing 700 g/ml G418 supple-
mented with 5% FCS. The medium was changed daily for 12 days until
individual colonies were visible. Single-cell clones that stably expressed
wild-type or mutant PCSK9 protein were isolated by limiting dilution
and screened for PCSK9 expression by immunoblotting using the anti-
FLAG monoclonal antibody. Cell lines expressing equivalent levels of
wild-type and mutant forms of PCSK9 were selected for further studies
and maintained in medium A containing 500 g of G418 supplemented
with 5% FCS.
Construction of Adenoviral Vectors Expressing Wild-type or Mutant
PCSK9 Proteins—Adenoviruses that express wild-type, S127R, F216L,
or S386A forms of human PCSK9 were constructed using AdEasy
system (Qbiogene, Carlsbad, CA) according to the manufacturer’s pro-
tocol. HindIII-XbaI fragments of pCMV-PCSK91-FLAG, pCMV-S127R,
pCMV-F216L, and pCMV-S386A were ligated to a HindIII-XbaI-di-
gested pShuttle-CMV vector. The resulting pShuttle constructs were
co-transformed with the pAdEasy-1 vector into BJ5183 cells to produce
recombinant adenoviral genomic constructs for wild-type and mutant
PCSK9 proteins. The recombinant adenoviral genomic constructs were
linearized with PacI and transfected into QBI-293A cells (Qbiogene)
cultured in DMEM supplemented with 5% FCS. Cells were overlaid
with 1.25% agarose/DMEM 20 h after transfection and further cultured
for 14 days until discrete plaques were identified. The resulting viral
plaques were assayed for PCSK9 expression by immunoblot analysis
using anti-FLAG antibody (Sigma).
Viruses expressing wild-type or mutant human PCSK9 proteins were
subjected to four rounds of amplification before purification by CsCl-
ultracentrifugation (28). All viruses were dialyzed against 10 mM Tris,
pH 8.0, 2 mM MgCl2, 4% sucrose buffer (29) and stored at 80 °C. Virus
titers were determined using a plaque-forming unit (PFU) assay in
QBI-293A cells (28). For administration to mice, the indicated amounts
of each recombinant adenovirus were injected as a single dose into tail
veins of nonfasted mice. Three days after injection, mice were killed,
and plasma and livers were harvested. Membrane fraction and nuclear
extract from liver were prepared as described (30).
Real Time Reverse Transcription-PCR—Total RNA was prepared
using an RNA STAT-60 kit (Tel-Test, Friendswood, TX). DNase I treat-
ment of total RNA was performed using a DNA-free kit (Ambion,
Austin, TX). cDNA was synthesized from 2 g of DNase-treated total
RNA using a TaqMan reverse transcription reagent kit and random
hexamer primers (Applied Biosystems, Foster City, CA). Specific prim-
ers for each gene were designed using PRIMER EXPRESS software
(Applied Biosystems) and previously published (31). The real time re-
verse transcription-PCR contained 20 ng of reverse-transcribed total
RNA, a 167 nM concentration of the forward and reverse primers, and
10 l of 2 SYBR Green PCRMaster Mix in a final volume of 20 l. The
PCRs were carried out using the Applied Biosystems Prism 7700 Se-
quence Detection System. All reactions were done in triplicate, and the
relative amounts of all mRNAs were calculated by using the compara-
tive CT method (46). Cyclophilin mRNA was used as the invariant
control.
Mice and Diets—Studies using wild-type mice were performed in
10–12-week-old male C57BL/6 mice purchased from The Jackson Lab-
oratory (Bar Harbor, ME). Mice with the genetic deletion of ARH
(Arh/) (21) were generously provided by Drs. JoachimHerz and Helen
Hobbs (University of Texas Southwestern Medical Center). Knockout
mice that lack the LDLR were previously described (32). All mice were
maintained on 12-h dark/12-h light cycles and fed a chow diet that
contained 4% (w/w) animal fat and 0.04% (w/w) cholesterol (Teklad
4% mouse/rat diet 7001 from Harlan Teklad Premier Laboratory Diets,
Madison, WI).
ApoB Synthesis and Secretion in Mouse Primary Hepatocytes—
C57BL/6J male mice (8–10 weeks of age) were injected with the indi-
cated adenovirus, and 3 days later primary hepatocytes were isolated as
described previously (33, 34). The hepatocytes were allowed to attach on
type I collagen-coated six-well plates for 2 h in Met/Cys-free DMEM
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(Sigma) supplemented with 5% NCLPDS, 4 mM L-glutamine, 100
units/ml penicillin G sodium, and 100 g/ml streptomycin sulfate (me-
dium E). The cells were then incubated with 200 Ci of [35S]Met/Cys
(Easy Tag EXPRESS-[35S] PROTEIN LABELING MIX; PerkinElmer
Life Sciences) in 1 ml of medium E for 2 h.
After incubation, the medium was collected, and protease inhibitors
(1 mM benzamidine, 0.5 mM phenylmethylsulfonyl fluoride, 2 g/ml
aprotinin, 5 mM EDTA, 10 mM HEPES, pH 8.0) were added. The cells
were harvested and lysed in a buffer containing 0.15 M NaCl, 5 mM
EDTA, 50 mM Tris-Cl, pH 7.4, 62.5 mM sucrose, 0.5% Triton X-100, 0.5%
sodium deoxycholate, 10 g/ml leupeptin, 5 g/ml pepstatin A, 0.5 mM
phenylmethylsulfonyl fluoride, 2 g/ml aprotinin, 25 g/ml ALLN, and
1 mM benzamidine.
To immunoprecipitate apoB, 500 g of cell extract or 0.5 ml of
medium was incubated with 10 g/ml of purified rabbit anti-mouse
apoB antibody (provided by Dr. Helen Hobbs) in 0.5 NET (0.15 M
NaCl, 5 mM EDTA, 50 mM Tris-Cl, pH 7.4, 0.5% Triton X-100, 0.1%
SDS). To immunoprecipitate albumin, 50 g of cell extract protein or 50
l of medium was incubated with 10 g/ml of rabbit anti-mouse albu-
min antibody (Biodesign International, Saco, ME). After a 6-h incuba-
tion with the antibodies, 30 l of protein A/G PLUS-agarose (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) was added and incubated at
4 °C for 16 h. The protein-antibody-protein A/G-agarose complexes were
washed five times with 500 l of NET. The immunoprecipitated pro-
teins were eluted in the loading buffer (0.125 M Tris-Cl, pH 6.8, 4% SDS,
20% glycerol, 10% 2-mercaptoethanol) by boiling for 5 min and then
separated on 4% SDS-PAGE gels (for apoB) or 8% gels (for albumin).
The gels were dried and exposed to a PhosphorImager plate. The
resulting signals were quantified using a PhosphorImager® Molecular
Dynamics Storm 820 system (Amersham Biosciences). ApoB values
were corrected for the amounts of labeled albumin synthesized and
secreted from the hepatocytes. Values are reported in arbitrary units of
relative counts for apoB/albumin.
RESULTS
To study the mechanism by which mutations in PCSK9 cause
elevated plasma LDL cholesterol concentrations, we first deter-
mined whether wild-type or mutant PSCK9 could proteolytically
activate SREBPs in an aberrant fashion. SREBPs are synthe-
sized as inactive precursors in the endoplasmic reticulum (ER).
To be active, the NH2-terminal segment of SREBP must be
released from the membrane to enter the nucleus (4). SREBP
activation requires SCAP, an escort protein that functions as a
sterol sensor and transports SREBPs from the ER to the Golgi
apparatus, and two proteases, designated site-1 protease (S1P)
and site-2 protease (S2P), located in the Golgi (35). When ER
membranes become depleted of cholesterol, SCAP escorts SREBP
to the Golgi, where it undergoes two sequential proteolytic cleav-
age events mediated by S1P, a membrane-bound subtilase-like
serine proteinase, and S2P, a membrane-bound zinc metallopro-
teinase. S1P belongs to the same family of subtilase-like serine
proteinase as does PCSK9; therefore, mutations in PCSK9 could
result in a gain of function that results in unregulated or aber-
rant cleavage of SREBPs, which in turn would increase lipid
biosynthesis and VLDL production.
To test this hypothesis, SRD-12B cells that harbor a genetic
deletion of S1P and are thus incapable of cleaving SREBPs
were transiently transfected with full-length SREBP-1a (Fig.
1A) or SREBP-2 (Fig. 1B) and either an empty vector, human
S1P, wild-type PSCK9, or mutant PCSK9 (S127R). Cells were
cultured either in the presence of sterols, conditions that nor-
mally suppress SREBP cleavage, or in the absence of sterols,
conditions that induce SREBP cleavage. Cellular membranes
and nuclear proteins were isolated, aliquots were separated by
SDS-PAGE, and immunoblot analyses were performed to de-
termine whether wild-type or mutant PCSK9 proteolytically
cleaved the membrane-bound SREBP-1a or SREBP-2 precur-
sor proteins.
As shown in Fig. 1, S1P restores normal sterol-regulated
cleavage of SREBP-1a (A) and SREBP-2 (B). The transfection
of wild-type PCSK9 results in equal expression of the propro-
tein (P) and cleaved (C) PCSK9 (compare P and C in Fig. 1, A
and B, lanes 6 and 7). Transfection of the S127R mutant
PCSK9 resulted in significantly less cleaved PCSK9. However,
neither wild-type PCSK9 nor mutant PCSK9 restored cleavage
FIG. 1. Cleavage of epitope-tagged SREBP-1 (A) and SREBP-2 (B) in SRD-12B cells transiently transfected with plasmids encoding
wild-type or mutant PCSK9. SRD-12B cells possessing a genetic deletion of S1P were set up at 5  105 cells/60-mm dish in medium A
supplemented with 5% FCS, 5 g/ml cholesterol, 1 mM sodium mevalonate, and 20 M sodium oleic acid on day 0. On day 1, cells were transfected
with the indicated plasmids (1 g of pTK-HSV-BP1 or pTK-HSV-BP2 and 0.5 g of pCMV-S1P-Myc or pCMV-PCSK9) using 6 l of Fugene 6 in
a final volume of 0.2 ml. On day 2, cells were washed twice with phosphate-buffered saline and switched to medium C containing 1% (w/v)
hydroxypropyl--cyclodextrin. After incubation at 37 °C for 1 h, cells were washed twice with phosphate-buffered saline and cultured in medium
C in the absence or presence of 1 g/ml 25-hydroxycholesterol plus 10 g/ml cholesterol added in a final concentration of 0.2% ethanol. After a 4-h
incubation, N-acetyl-leucinal-leucinal-norleucinal (25 g/ml) was added for 1 h, after which the cells were harvested and processed as described
under “Experimental Procedures.” Aliquots (30 g) of cell membrane and nuclear extract protein were subjected to 8% SDS-PAGE and transferred
to nitrocellulose filters for immunoblot analysis. The filters were incubated with the following primary antibodies: anti-HSV for SREBP-1 and
SREBP-2, anti-Myc for S1P, and anti-FLAG for PCSK9. Bound primary antibodies were visualized using a peroxidase-conjugated affinity-purified
donkey anti-mouse IgG secondary antibody. P and N denote the precursor and cleaved nuclear forms of SREBP-1 and SREBP-2, respectively. P
and C for PCSK9 denote the proprotein and cleaved forms of PCSK9, respectively. Similar results were obtained in three independent experiments.
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of SREBP-1a (Fig. 1A) or SREBP-2 (Fig. 1B) in the presence or
absence of sterols. These results demonstrate that mutations in
PCSK9 do not increase plasma LDL cholesterol levels by by-
passing the role of S1P in processing SREBPs.
To determine whether wild-type and mutant PCSK9 pro-
teins alter LDLR expression or function, wild-type CHO-K1 cell
lines were stably transfected with CMV-driven wild-type
PCSK9 or mutant PCSK9 cDNAs encoding either the S127R
mutation or the F216L mutation. The PCSK9 proteins con-
tained a FLAG epitope tag at the COOH terminus. Three
clones with equivalent levels of PCSK9 expression were iden-
tified, and the expression and function of the LDLR were as-
sessed. As shown in Fig. 2A, the amount of wild-type and
mutant PCSK9 proteins expressed was similar in the three cell
lines, although the S127R mutation resulted in a reduction in
the relative proportion of cleaved PCSK9 (A, lower band). The
amounts of secreted wild-type and F216L mutant were also
equivalent, whereas the amount of secreted S127R appeared to
be slightly lower in amount. The LDLR protein immunoblots
showed two bands. The lower band represents the precursor
form that is present in the ER. The upper band represents the
mature receptor that has undergone O-linked glycosylation in
the Golgi (36). The amount of mature LDLR protein was unaf-
fected by wild-type or mutant PCSK9 overexpression. The
slight reduction in the amount of the precursor form of the
LDLR observed in the transfected cells was not a consistent
finding. In addition, assays of LDLR function that measured
LDL binding and uptake were also not consistently different
among the four immortalized hamster ovarian cell lines (data
not shown).
The studies described above were performed in immortalized
hamster ovarian cells. Mutations in ARH, an adaptor protein
that binds to the cytoplasmic domain of the LDLR and is
required for the internalization of the LDLR, cause hypercho-
lesterolemia by reducing LDL clearance predominantly in the
liver and lymphocytes (37–39). Therefore, we hypothesized that
PCSK9 could have a greater function in hepatocytes than in
other cell types. To test this hypothesis, adenoviral constructs
that express the wild-type or mutant PCSK9 proteins were
produced and used to infect HepG2 cells, a human hepatoma
cell line. As shown in Fig. 2B, adenovirus-mediated overexpres-
sion of wild-type PCSK9 or either mutant PCSK9 resulted in
the near absence of detectable LDLR protein, suggesting that
PCSK9 may have cell type-specific activity.
FIG. 2. LDLR expression in CHO-K1 and HepG2 cells transfected with wild-type or mutant forms of PCSK9. A, CHO-K1 cells stably
transfected with pcDNA3 (CHO-K1), pCMV-PCSK9 (WT-PCSK9), pCMV-S127R (S127R), or pCMV-F216L (F216L) were grown in monolayer
cultures as described under “Experimental Procedures.” For immunoblot analysis, 30 g of cell lysate protein was subjected to 8% SDS-PAGE,
transferred to a nitrocellulose membrane, and blotted with primary antibodies directed against FLAG, LDLR, and RAP. Aliquots of media from
stably transfected cells in each group were trichloroacetic acid-precipitated, and the proteins were resuspended in SDS sample buffer as described
under “Experimental Procedures.” Aliquots corresponding to 100 l of pooled medium were subjected to 8% SDS-PAGE, and immunoblot analysis
was performed using an anti-FLAG primary antibody and a peroxidase-conjugated affinity-purified donkey anti-mouse IgG secondary antibody.
B, HepG2 cells were set up at 5  105 cells/60-mm dish in medium D supplemented with 10% FCS on day 0. On day 1, cells were infected with
adenovirus (5  107 PFU) expressing -galactosidase (-Gal), wild-type (WT-PCSK9), S127R mutant (S127R), or F216L mutant (F216L) PCSK9
in 1 ml of medium D for 2 h. After a 2-h incubation, an additional 1 ml of medium D supplemented with 20% NCLPDS was added, and the cells
were incubated overnight at 37 °C. After an overnight incubation, the cells were harvested and processed as described under “Experimental
Procedures.” Aliquots (30 g) of cell membrane and 5 l of media were subjected to 8% SDS-PAGE and transferred to nitrocellulose filters for
immunoblot analysis. An anti-FLAG primary antibody was used to detect PCSK9 protein, and all other proteins were detected using the primary
antibodies as described under “Experimental Procedures.” P and C for PCSK9 denote the proprotein and cleaved forms of PCSK9, respectively.
These experiments were repeated twice with similar results.
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To determine whether PCSK9 functioned in a similar man-
ner in vivo in the liver, wild-type mice were injected with
equivalent amounts of adenovirus expressing -galactosidase,
wild-type PCSK9, or the two mutant versions of PCSK9 (Fig.
3A). The level of total PCSK9 protein expressed was similar in
all mice; however, the cleaved form of PCSK9 for the S127R
mutation was consistently less plentiful than that seen for the
wild-type PCSK9 and the F216L mutant forms of PCSK9.
LDLR protein levels were markedly reduced in the livers of
mice overexpressing either the wild-type or one of the mutant
forms of PCSK9 (compare lanes 5–16 with lanes 1–4). The
protein levels of LDL receptor-related protein (LRP), a member
of the LDLR family (40), and ARH, an adaptor protein involved
in hepatic LDLR internalization, were not altered by PCSK9
overexpression. Similarly, no consistent effects were observed
in the expression of the precursor and nuclear forms of
SREBP-1 and SREBP-2 in the mice expressing recombinant
PCSK9. These results demonstrated that wild-type or mutant
PCSK9 overexpression was associated with a dramatic reduc-
tion in the amount of LDLR protein in livers of mice.
To determine whether the reduction of LDLR protein was
due to reduced LDLR transcription, we measured LDLRmRNA
levels in the livers of the adenovirus-infected mice by real time
PCR. No significant differences in LDLR mRNA levels were
found in the mice expressing wild-type or mutant PCSK9 pro-
tein (Fig. 3B). The mRNA levels for apoB and several genes
involved in cholesterol and fatty acid biosynthesis, including
3-hydroxy-3-methylglutaryl-CoA synthase, 3-hydroxy-3-meth-
ylglutaryl-CoA reductase, squalene synthase, acetyl-CoA car-
boxylase, and fatty acid synthase, also were not significantly
different across groups (data not shown).
The marked reduction in hepatic LDLR expression associ-
ated with either wild-type or mutant PCSK9 overexpression
resulted in a 1.5–2-fold increase in total plasma cholesterol
concentrations (Fig. 4A). Separation of plasma lipoproteins by
FPLC demonstrated that overexpression of all PCSK9 proteins
resulted in a selective increase in plasma LDL cholesterol (Fig.
4B). A slightly greater increase in plasma levels of LDL cho-
lesterol was associated with the expression of wild-type PCSK9
and the F216L mutant protein than with the S127R mutant.
This difference may be related to less cleaved form of the
PCSK9 protein produced in the mice expressing the S127R
mutant form of the enzyme (Fig. 3A).
To determine whether the ability of PCSK9 to reduce the
LDLR protein was dependent on the catalytic activity of
PCSK9, an amino acid in the catalytic triad of human PCSK9
that is required for its proteolytic activity was mutated. A
conserved serine at position 386 was changed to alanine
(S386A), and the resulting cDNA was inserted into an adeno-
viral vector for injection into mice. The alanine substitution
eliminated the autocatalytic cleavage activity of PCSK9 pro-
tein, as evidenced by the absence of the cleaved form of the
protein (Fig. 5, lanes 5–8 and 9–12). The level of LDLR protein
in livers of mice injected with the S386A mutant was essen-
tially the same as that of the control mice injected with the
-galactosidase virus. These results suggested that the ability
of PCSK9 to reduce the amount of LDLR protein was depend-
ent on a functional catalytic domain.
The above experiments demonstrated that PCSK9, when
overexpressed, reduced the amount of LDLR protein in liver.
The normal function of the LDLR is dependent on an adaptor
protein, ARH, for internalization (41, 42). In the absence of
ARH, LDLRs accumulate on the cell surface of the hepatocyte
due to a failure to undergo internalization (21, 42). To deter-
mine whether the ability of PCSK9 to reduce LDLR protein in
liver required functional ARH, mice lacking ARH were injected
with control or wild-type PCSK9 virus, and the amount of
LDLR protein was measured. The immunoblots in Fig. 6 show
that overexpression of PCSK9 in livers of Arh/ mice resulted
in a reduction of hepatic LDLR protein. These findings sug-
gested that PCSK9-mediated reduction in LDLR protein was
not dependent on functional ARH and thus occurred either en
route from the synthesis of the receptor in the ER to the cell
surface or on the cell surface prior to internalization of the
LDLR.
FIG. 3. LDLR levels in livers of mice injected with an adenovi-
rus expressing -galactosidase, wild-type PCSK9, or mutant
PCSK9. 10-week-old male C57BL/6J mice were injected with adenovi-
rus (2  109 PFU in 200 l) expressing -galactosidase (-Gal), wild-
type (WT-PCSK9), S127R mutant (S127R), or F216L mutant (F216L)
PCSK9. Four days after injection, mice were sacrificed, and plasma and
livers were collected. Each lane represents an individual mouse. A,
immunoblot analyses of PCSK9, LDLR, LRP, ARH, transferrin receptor
(membrane fraction), SREBP-1, SREBP-2 (membrane and nuclear frac-
tions), and cAMP-responsive element-binding protein (CREB; nuclear
fraction). An aliquot (30 g) of protein derived from individual mouse
livers was subjected to 8% SDS-PAGE and transferred to nitrocellulose
membrane for immunoblot analysis. An anti-FLAG primary antibody
was used to detect PCSK9 protein, and all other proteins were detected
using the primary antibodies as described under “Experimental Proce-
dures.” P and N denote the precursor and cleaved nuclear forms of
SREBP-1 and SREBP-2. P and C for PCSK9 denote the proprotein and
cleaved forms of PCSK9, respectively. B, relative amounts of LDLR
mRNA in livers of mice injected with the indicated adenoviruses. Total
RNA from individual mouse livers was prepared and subjected to re-
verse transcription-PCR quantification as described under “Experimen-
tal Procedures.” Each value represents the amount of mRNA relative to
that in the first mouse (lane 1) injected with -galactosidase virus,
which is arbitrarily defined as 1. Cyclophilin was used as an invariant
control (data not shown). Similar results were obtained in four inde-
pendent experiments.
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A recent report describing the phenotype of human subjects
harboring the S127R mutation suggested that the principal
metabolic defect responsible for hypercholesterolemia in these
individuals is increased apoB secretion (43). To test this possi-
bility, apoB synthesis and secretion were measured in primary
hepatocytes derived from mice injected with adenoviruses ex-
FIG. 4. Concentrations of total
plasma cholesterol and FPLC pro-
files of plasma cholesterol from mice
injected with an adenovirus express-
ing -galactosidase, wild-type PCSK9,
ormutant PCSK9.A, the concentration of
total cholesterol in plasma from each
mouse described in the legend to Fig. 3 was
measured as described under “Experimen-
tal Procedures.” B, plasma from mice de-
scribed in the legend to Fig. 3 was pooled
and subjected to gel filtration by FPLC.
The concentration of total cholesterol in
each fraction was measured as described
under “Experimental Procedures.”
FIG. 5. Immunoblot analysis of LDLR protein in livers of mice injected with an adenovirus expressing the S386A mutant PCSK9.
10-week-old male C57BL/6J mice were injected with adenovirus (2  109 PFU in 200 l) expressing -galactosidase (-Gal), wild-type (WT-
PCSK9), or S386A mutant (S386A) PCSK9. Four days after injection, mice were sacrificed, and livers were harvested for immunoblot analysis as
described in the legend to Fig. 3. P and C for PCSK9 denote the proprotein and cleaved forms of PCSK9, respectively. Each lane is the result from
an individual mouse. Similar results were obtained in three independent experiments.
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pressing -galactosidase, wild-type PCSK9, or one of the mu-
tant forms of PCSK9 (S127R). As shown in Fig. 7A, the PCSK9
proteins were expressed in the primary hepatocytes, and the
expression of the LDLR was significantly reduced when either
the wild-type or mutant form of PCSK9 was expressed in these
cells. No significant differences in the amount of apoB synthe-
sized or secreted from the primary hepatocytes were found
between the primary hepatocytes from the mice expressing the
wild-type PCSK9 or the S127R mutant compared with the
-galactosidase control (Fig. 7B).
To confirm these findings in vivo, mice that lack the LDLR
(Ldlr/) were injected with adenoviruses expressing wild-
type PSCK9. If PSCK9 functions to increase apoB secretion,
then plasma VLDL and/or LDL cholesterol levels should be
increased in the Ldlr/ mice expressing wild-type PCSK9,
since the LDLR is the major route of clearance of VLDL and
LDL from plasma. Plasma VLDL and LDL cholesterol levels
were not increased in Ldlr/ mice injected with the wild-type
PCSK9 adenovirus (Fig. 8A), despite documented expression of
both the precursor and cleaved forms of the protein in the livers
of the mice (Fig. 8B). Thus, no evidence was found to indicate
that the increased plasma levels of LDL cholesterol associated
with hepatic PCSK9 expression were due to increased apoB
secretion in mice.
DISCUSSION
The current studies suggest that PCSK9 acts through a
post-transcriptional mechanism to negatively regulate LDLR
protein levels. Overexpression of PCSK9 reduced LDLR pro-
tein, resulting in an increase in plasma levels of LDL choles-
terol. Surprisingly, overexpression of the wild-type as well as
the mutant forms of PCSK9 associated with hypercholesterol-
emia in humans reduced LDLR protein levels to similar low
levels. In contrast, inactivation of the catalytic activity of
PCSK9 had no effect on liver LDLR protein levels. These data
suggest that the mutations causing hypercholesterolemia
cause a gain of function in PCSK9 that ultimately results in
hypercholesterolemia.
PCSK9 appears to reduce expression of the LDLR through a
post-transcriptional mechanism that acts prior to internaliza-
tion and recycling of the LDLR. This was demonstrated by
determining whether PCSK9 overexpression altered the ex-
pression of the LDLR protein in livers of mice that lack ARH
(Fig. 7). ARH is an adaptor protein that binds to the cytoplas-
mic domain of the LDLR and is required for endocytosis and
subsequent recycling of the LDLR to the cell surface (37, 41,
42). PCSK9 overexpression in Arh/ mice markedly reduced
the amount of LDLR protein. The observed level of reduction
was similar to that in mice with functional ARH, suggesting
that PCSK9 mediates LDLR degradation at a point in the
transit of the LDLR to the cell surface or when the LDLR is on
the cell surface. Studies designed to elucidate the cellular site
at which PCSK9 functions are currently in progress.
PCSK9 overexpression does not appear to alter apoB synthe-
sis and secretion in mice. Primary hepatocytes derived from
mice injected with adenoviruses expressing wild-type and mu-
tant PCSK9 proteins exhibited no significant differences in
apoB secretion (Fig. 7), and overexpression of PCSK9 in livers
of Ldlr/ animals did not alter VLDL or LDL cholesterol
levels. These data support the conclusion that PCSK9 does not
increase apoB secretion from liver but rather affects plasma
levels of LDL cholesterol by reducing LDLR activity directly.
Maxwell and Breslow (44) reported studies using adenoviral
overexpression of wild-type mouse PCSK9 in mice. The current
studies confirm and extend these observations to normal hu-
man PSCK9 protein and demonstrate that two altered versions
of PCSK9 with mutations found in families with hypercholes-
terolemia have similar activities when overexpressed in mouse
liver. Furthermore, a catalytically inactive version of PCSK9
was shown not to alter LDLR expression (Fig. 5).
Several important questions regarding the function of
PCSK9 remain unresolved. First, does PCSK9 cleave the LDLR
directly, or does PCSK9 cleave another unidentified protein
involved in LDLR trafficking or stability? A computer search
for sequences that correspond to those recognized and cleaved
by PCSK9 did not reveal any potential cleavage sites in the
LDLR (6). However, it remains possible that the LDLR is
FIG. 6. Immunoblot analysis of LDLR receptor in livers of Arh/ mice injected with adenovirus expressing wild-type PCSK9.
10-week-old male wild-type and Arh/ mice were injected with adenovirus (2  109 PFU in 200 l) expressing -galactosidase (-Gal) and
wild-type PCSK9 (WT-PCSK9). Four days after injection, mice are sacrificed, and livers were processed for immunoblot analysis as described in
the legend of Fig. 3. The results of one wild-type mouse injected with the -galactosidase included as a positive control for the ARH antibody. P
and C for PCSK9 denote the proprotein and cleaved forms of PCSK9, respectively. Each lane represents results from an individual mouse.
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directly cleaved by PCSK9 at an as yet unidentified sequence.
Studies in cultured cells indicate that PCSK9 is not equally
active in all immortalized cell types (Fig. 2). In addition to
HepG2 cells, PCSK9 overexpression reduces the expression of
the LDLR in HEK 293 cells but not in cultured human fibro-
blasts or in the Huh7 human hepatoma cells.2 Since all of these
cultured cells express the LDLR protein, these observations
raise the possibility that PCSK9 requires an additional protein
or proteins not present in all cell types to effectively reduce
LDLR.
A second question is whether PCSK9 functions intracellu-
larly or as a secreted protein. If the secreted form of PCSK9
cleaves the LDLR, it could reduce the expression of the receptor
in tissues that do not express PCSK9 (i.e. act in trans). Along
these lines, we measured LDLR protein expression in other
tissues from mice overexpressing PCSK9 in liver and found a
marked reduction in LDLR protein in the adrenal gland (data
not shown). Real time PCR analysis revealed very low levels of
human PCSK9 mRNA in this and other tissues, which pre-
cludes definitive conclusions regarding the possibility that
PCSK9 may be active in plasma.
A third unanswered question is how missense mutations in
PCSK9 cause hypercholesterolemia in humans. Our studies did
not reveal measurable differences in the ability of mutant and
wild-type PCSK9 protein to reduce LDLR expression in liver.
2 S. W. Park and J. D. Horton, unpublished observations.
FIG. 7. ApoB synthesis and secretion in primary hepatocytes
derived frommice injected with an adenovirus expressing -ga-
lactosidase, wild-type PCSK9, or mutant PCSK9. C57BL/6 male
mice (10–12 weeks of age) were injected with the indicated adenovirus,
and 3 days later primary hepatocytes were isolated and cultured as
described under “Experimental Procedures.” A, PCSK9 and LDLR pro-
tein levels in primary hepatocytes derived from mice injected with the
indicated adenovirus at the end of the 2-h incubation. Aliquots (30 g)
of cell lysate were subjected to 8% SDS-PAGE and transferred to nitro-
cellulose filters for immunoblot analysis as described in the legend of
Fig. 3. P and C for PCSK9 denote the proprotein and cleaved forms of
PCSK9, respectively. B, apoB synthesis and secretion from primary
hepatocytes derived from mice injected with the indicated adenovirus.
The primary hepatocytes were labeled for the indicated times in 1 ml of
medium E supplemented with [35S]Met/Cys (200 Ci/ml, 1175 Ci/
mmol). After labeling, cell lysate and the media were processed for
immunoprecipitation as described under “Experimental Procedures.”
The protein-antibody complexes were eluted from protein A/G-agarose
by boiling for 5 min in the loading buffer and subjected to 4% (apoB) or
8% (albumin) SDS-PAGE. The gels were dried and exposed to a Phos-
phorImager plate, and the amounts of labeled apoB and albumin in cell
extract and medium were quantified using an Amersham Biosciences
Storm 820 system. ApoB values were corrected for the amounts of
labeled albumin synthesized and secreted from the hepatocytes. Each
value represents the average of duplicate incubations. Similar results
were obtained in three independent experiments.
FIG. 8. FPLC profiles from Ldlr/ mice before and after the
injection of adenoviruses expressing wild-type PCSK9. 7–12-
week-old Ldlr/ female mice were injected with adenovirus (5  109
PFU in 200 l) expressing wild-type PCSK9 (WT-PCSK9). Blood was
obtained for FPLC analysis prior to adenoviral injections (day 0) and 3
days after adenoviral injections (day 3). On day 3, livers also were
harvested for immunoblot analysis. A, FPLC profiles of Ldlr/ injected
with the wild-type PCSK9 on day 0 (open circle) and day 3 (solid circle).
B, immunoblot analysis of human PCSK9 in livers of mice injected with
adenovirus expressing wild-type PCSK9. PCSK9 and RAP immunoblots
were carried out as described in the legend to Fig. 3. Each lane repre-
sents results from an individual mouse. P and C for PCSK9 denote the
proprotein and cleaved forms of PCSK9, respectively. Similar results
were obtained in one additional independent experiment.
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Therefore, we cannot definitively explain why individuals who
harbor a mutant form of PCSK9 develop hypercholesterolemia.
The phenotypes observed in individuals with mutations in
PCSK9 are inherited in an autosomal dominant manner; there-
fore, it is predicted that mutations in PCSK9 result in a gain of
function that ultimately results in hypercholesterolemia. If
this is the case, the most likely explanation for our results is
that the mutated forms of PCSK9 result in a subtle increase
in PCSK9 activity compared with the wild-type PCSK9 pro-
tein, but the increased activity is masked by the level of
overexpression.
An alternative explanation for our results is that the high
level of overexpression PCSK9 achieved with adenoviral infec-
tion elicits an activity that is not physiological. Although this
possibility cannot be excluded in the current studies, it is less
likely, since the mutations in PCSK9 result in increased
plasma levels of LDL cholesterol, and all previously defined
mutations that result in elevated plasma LDL are due to
changes in the ability of the LDLR to clear apoB-containing
lipoproteins (10). Definitive studies demonstrating a difference
in activity between wild-type and mutant PCSK9 proteins will
require studies in mice that lack PCSK9 as well as knockin
mice that express mutant forms of PCSK9 expressed at phys-
iologic levels.
The current and previous studies (3, 5, 44) demonstrate that
plasma LDL cholesterol levels are principally determined by
the expression of LDLRs in liver, which is regulated both
transcriptionally and post-transcriptionally. Both mecha-
nisms, however, are regulated by a single transcription factor
family, the SREBPs, since these control the expression of both
the LDLR and PCSK9 genes. The biological reason why
SREBPs transcriptionally activate both the LDLR and PCSK9,
a protein that apparently reduces LDLR protein levels, cannot
be easily reconciled with our current information. It has previ-
ously been shown that the half-life of the LDLR protein in
fibroblasts is 25 h (45). Therefore, the simultaneous tran-
scriptional activation of PCSK9 by SREBPs may provide a
post-transcriptional mechanism to degrade the LDLR and
shorten the protein half-life, which could protect the cell from
excessive LDL uptake and cholesterol accumulation. If this is
the case, then an inhibitor of PCSK9 function may increase
LDLR protein levels and enhance LDL clearance from the
plasma. Confirmation of the function of PCSK9 and its poten-
tial value as a therapeutic target for the treatment of hyper-
cholesterolemia will require studies in mice that lack PCSK9.
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